[Treatment of relapsed and refractory EZB/C3 subtype DLBCL with chidamide in combination of R2-CHOP: a case report]

Zhonghua Xue Ye Xue Za Zhi. 2021 May 14;42(5):436-437. doi: 10.3760/cma.j.issn.0253-2727.2021.05.016.

[Article in Chinese]

Authors

L Yang¹, W Zhang¹, M L Zhang¹, K F Shen¹, J C Wang¹, Y Q Guan¹, H D Cai¹, Y H Bao¹, M Xiao¹, J F Zhou¹, M Zheng¹

Affiliation

¹ Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.

PMID: 34218590
PMCID: PMC8293004
DOI: 10.3760/cma.j.issn.0253-2727.2021.05.016

No abstract available

Publication types

Case Reports

MeSH terms

Aminopyridines* / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Benzamides / therapeutic use
Humans
Lymphoma, Large B-Cell, Diffuse* / drug therapy
Rituximab / therapeutic use

Substances

Aminopyridines
Benzamides
Rituximab
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide

Grants and funding

基金项目：国家自然科学基金面上项目（81974005）；国家自然科学基金青年基金（81700145）